174649-09-3 (R)-N-[3-(3-氟-(4-吗啉基)苯基)-2-氧代-5-噁唑烷基]甲醇甲磺酸酯

中文名称: (R)-N-[3-(3-氟-(4-吗啉基)苯基)-2-氧代-5-噁唑烷基]甲醇甲磺酸酯
英文名称: (R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate
CAS号

词条详情加载中…

名称和标识

中文名: (R)-N-[3-(3-氟-(4-吗啉基)苯基)-2-氧代-5-噁唑烷基]甲醇甲磺酸酯
英文名: (R)-(3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl)methyl methanesulfonate
CAS号: 174649-09-3
分子式: C15H19FN2O6S
分子量: 374.385
中文别名: (R)-[3-(3-氟-4-吗啉苯基)-2-氧-5-噁唑烷基]甲醇甲磺酸酯; (R)-N-[3-(3-氟-(4-吗啉基)苯基)-2-氧代-5-唑烷基]甲醇甲磺酸酯; (R)-N-[3-(3-氟-4-(4-吗啉)苯基)-2-氧-5-噁唑烷基]甲醇甲磺酸酯; 利奈唑胺相关杂质; 利奈唑胺USP RC D
英文别名: [(5R)-3-(3-fluoro-4-morpholin-4-ylphenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl methanesulfonate; (R)-[3-(3-Fluoro-4-Morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl methanesulfonate; (R)-(3-(3-flouro-4-Morpholinophenyl)-2-oxo-5-oxazolidinyl)methyl methanesulfonate; (5R)-3-[3-Fluoro-4-(4-Morpholinyl)phenyl]-5-[[(Methylsulfonyl)oxy]Methyl]-2-oxazolidinone; 2-Oxazolidinone, 3-[3-fluoro-4-(4-Morpholinyl)phenyl]-5-[[(Methylsulfonyl)oxy]Methyl]-, (5R)-; Linezolid related Compound; Linezolid USP RC D; {(5R)-3-[3-Fluoro-4-(4-morpholinyl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl methanesulfonate; Linezolid Impurity 32

物化属性

CYP1A2 inhibitor: No
CYP2C19 inhibitor: Yes
CYP2C9 inhibitor: No
CYP2D6 inhibitor: No
CYP3A4 inhibitor: No

安全信息

安全说明

运输方式为冰袋运输。危险性质：非危险化学品。WGK Germany: WGK 3。海关编码: 2934990002。存储类别: 11 - 可燃固体。

生产及用途

用途与制备

化学合成；是利奈唑胺合成的中间体，利奈唑胺是对许多病原微生物具有抗微生物活性的近期合成类抗菌剂。

医药

合成路线 1（1. 合成：174649-09-3）

步骤：在0℃下向132.8g（R）-N-[[3-[3-氟-4-吗啉基]苯基]-2-氧代-5-恶唑烷基]甲醇和87.1g三乙胺在二氯甲烷的溶液中，在氮气下加入74克甲磺酰氯。将反应混合物在0℃下搅拌30分钟，然后温热至环境温度。沉淀出白色固体。加入1.75L水、6.50L二氯甲烷和1L乙酸乙酯混合物，继续搅拌30分钟。过滤反应物质，得到白色固体。
条件：With triethylamine In dichloromethane at 0℃; for 0.50 h;
产率：140克；百分比：105.42％w/w
参考文献：[1] Patent: WO2009/63505, 2009, A2. Location in patent: Page/Page column 14 [2] Patent: EP2163547, 2010, A1. Location in patent: Page/Page column 8 [3] Patent: WO2011/77310, 2011, A1. Location in patent: Page/Page column 12; 13 [4] Synthetic Communications, 2010, vol. 40, # 6, p. 789 - 798 [5] Patent: WO2010/84514, 2010, A2. Location in patent: Page/Page column 15 [6] Patent: WO2011/114210, 2011, A2. Location in patent: Page/Page column 23 [7] J. Med. Chem., 1996, vol. 39, # 3, p. 673 - 679 [8] Tetrahedron Letters, 1999, vol. 40, # 26, p. 4855 - 4856 [9] Chemical and Pharmaceutical Bulletin, 2001, vol. 49, # 4, p. 353 - 360 [10] Tetrahedron Letters, 2006, vol. 47, # 38, p. 6799 - 6802 [11] European Journal of Medicinal Chemistry, 2009, vol. 44, # 8, p. 3217 - 3227 [12] Organic and Biomolecular Chemistry, 2008, vol. 6, # 24, p. 4634 - 4642 [13] Patent: WO2012/114355, 2012, A1. Location in patent: Page/Page column 11 [14] Patent: WO2013/72923, 2013, A1. Location in patent: Page/Page column 16-17 [15] European Journal of Medicinal Chemistry, 2013, vol. 69, p. 779 - 785 [16] Patent: US2013/324719, 2013, A1. Location in patent: Paragraph 0022; 0056-0057 [17] Patent: WO2015/68121, 2015, A1. Location in patent: Page/Page column 15

174649-09-3 (R)-N-[3-(3-氟-(4-吗啉基)苯基)-2-氧代-5-噁唑烷基]甲醇甲磺酸酯 - 化工 AI 网